
Last updated: 2026-09-09 05:10:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Grace Therapeutics, Inc. (GRCE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.11, with a market capitalization of $44.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.79 to $5.18. This page covers its latest market performance, valuation, price trends and company information.
$44.18M | |
$2.09 | |
$5.18 | |
$1.75 | |
$2.10 | |
158.41K | |
215.74K | |
-- | |
$5.18 | |
$1.79 | |
-- | |
-- |
Grace Therapeutics, Inc. (GRCE) last closed at $2.10 as of 2026-09-08 23:31:00, unchanged from the previous close of $2.10.
During the latest regular trading session, GRCE traded between $1.75 and $5.18, with a volume of 158.41K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Grace Therapeutics, Inc. (GRCE) moved from $2.16 to $2.11, representing a decline of 2.18% ($0.05).
The stock traded between $2.06 and $2.20 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 105.66 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9.5%
GRCE is currently trading at $2.11, placing it 9.5% of the way from its 52-week low of $1.79 to its 52-week high of $5.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Grace Therapeutics, Inc. (GRCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.